Cytokinetics Inc (CYTK)
59.69
-0.23
(-0.38%)
USD |
NASDAQ |
May 17, 11:46
Cytokinetics Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2011 | 8.891M |
| June 30, 2011 | 10.51M |
| March 31, 2011 | 9.179M |
| December 31, 2010 | |
| September 30, 2010 | 9.547M |
| June 30, 2010 | 10.24M |
| March 31, 2010 | 9.068M |
| December 31, 2009 | 9.822M |
| September 30, 2009 | 9.857M |
| June 30, 2009 | 10.20M |
| March 31, 2009 | 9.959M |
| December 31, 2008 | 11.47M |
| September 30, 2008 | 13.52M |
| June 30, 2008 | 14.86M |
| March 31, 2008 | 14.10M |
| December 31, 2007 | 13.96M |
| September 30, 2007 | 13.22M |
| June 30, 2007 | 13.73M |
| Date | Value |
|---|---|
| March 31, 2007 | 12.49M |
| December 31, 2006 | 13.03M |
| September 30, 2006 | 12.54M |
| June 30, 2006 | 12.40M |
| March 31, 2006 | 11.27M |
| December 31, 2005 | 10.74M |
| September 30, 2005 | 9.259M |
| June 30, 2005 | 10.04M |
| March 31, 2005 | 10.54M |
| December 31, 2004 | 11.21M |
| September 30, 2004 | 9.535M |
| June 30, 2004 | 9.777M |
| March 31, 2004 | 9.36M |
| December 31, 2003 | |
| September 30, 2003 | |
| June 30, 2003 | 7.286M |
| March 31, 2003 | 7.756M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.343B |
| Johnson & Johnson | 3.542B |
| Eli Lilly and Co | 2.523B |
| Viking Therapeutics Inc | 24.10M |
| Madrigal Pharmaceuticals Inc | 71.24M |